Novartis acquires IFM Therapeutics’ subsidiary IFM Due in deal worth up to $835m
Under the agreement, Novartis made fixed payments to fully fund IFM Due’s research and development expenses for the…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Mar 24
Under the agreement, Novartis made fixed payments to fully fund IFM Due’s research and development expenses for the…
12 Mar 24
The asset sale consists of the majority of the company's workforce and most of its clinical equipment and…
23 Feb 24
Blueprint Medicines will be paid a purchase price of $15m, of which $10m is due upon Rigel's first…
22 Feb 24
The deal is expected to enable Dario to create a complete digital offering in the market for chronic…
13 Feb 24
ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic…
08 Feb 24
Under the terms of the deal, Jazz will secure all rights, patents, title, and interest in exchange for…
08 Feb 24
QSAM is focused on the development of therapeutic radiopharmaceuticals for primary and metastatic bone cancer and its initial…
06 Feb 24
The acquisition is expected to further expand and complement Novartis’ oncology pipeline while helping the firm to develop…
02 Feb 24
The deal involves Fountain Valley Regional Hospital, Lakewood Regional Medical Center, Los Alamitos Medical, Placentia-Linda Hospital, and other…
23 Jan 24
The acquisition is expected to strengthen Sandoz’s ophthalmology portfolio in the US and includes the BLA, product inventory,…